Type: Prelims Only

Why In The News?

Pharmacogenomics is transforming healthcare by showing how genetic differences affect individual drug responses. This breakthrough emerging technology is replacing traditional “start low, go slow” trial-and-error prescribing with personalised, precision-based treatment that improves effectiveness and reduces harmful reactions.

1) What is Pharmacogenomics?

• Definition & Purpose: Studies how genetic variations affect drug response, determining whether a drug will be effective, ineffective, or harmful.
• Role of Enzymes: Differences in drug-metabolising enzymes, especially the CYP450 family, impact the metabolism of ~75% of common drugs.
• Metaboliser Phenotypes:
  • Poor Metaboliser: Low enzyme activity → toxic drug buildup at standard doses.
  • Ultrarapid Metaboliser: High enzyme activity → reduced therapeutic benefit.
• Widespread Variants: About 90% of people carry at least one actionable pharmacogenetic variant.
• Clinical Impact: Genetic factors significantly contribute to adverse drug reactions (ADRs), a major cause of hospitalisation and death in developed nations.

2) Understanding the Problem in Traditional Prescribing:

• Traditional Approach – “Start Low, Go Slow”: Reflects the challenge that the same drug and dose can heal one patient but harm another.
• Population-Based Prescribing: For decades, medications were prescribed based on population averages, leading to trial-and-error treatment.
• Shift Toward Precision: Pharmacogenomics is transforming this approach by showing how genes influence drug response, moving from guesswork to precision.

3) Real-World Applications:

• Warfarin Dosing:
  • Variants in CYP2C9 and VKORC1 explain ~50% of dose variation.
  • Genetic-guided dosing reduces bleeding risk and allows faster achievement of therapeutic levels.
• Clopidogrel Activation:
  • Requires CYP2C19 for activation.
  • CYP2C19*2 variants (25–30%) → poor activation → higher risk of stent thrombosis.
  • CPIC 2022 guidelines recommend alternatives for poor metabolisers.
• Psychiatry:
  • Many antidepressants/antipsychotics rely on CYP2D6 and CYP2C19.
  • Testing reduces side effects, improves symptom control, and lowers costs.
• Oncology: Rapid progress in using genetic markers to personalise cancer treatment.

4) Economic Considerations:

• Cost Reduction: Genetic test prices have dropped from thousands to $200-500 for large panels.
• Cost–Effectiveness:
  • Testing prevents adverse events and improves outcomes, proving cost-effective, especially in chronic diseases.
• Evaluation Framework: Value depends on factors such as severity of side-effects, frequency of variants, availability of alternative drugs, and variability in clinical settings.
• Preventive Value: Avoiding even one serious ADR can offset the cost of testing many patients.

5) Implementation Challenges:

• Provider Knowledge Gaps: Most clinicians lack training in pharmacogenomics, making interpretation difficult.
• Infrastructure Limitations: Electronic health records often lack tools to integrate genetic data into prescribing workflows.
• Reimbursement Issues: Insurance coverage remains inconsistent, creating hesitation.
• Regulatory Complexity:
  • Over 100 FDA drug labels include pharmacogenomic information.
  • Some provide actionable guidance; others are only informative.
• Cultural & Institutional Barriers: Requires changes in clinical culture, administrative support, and trained champions to lead adoption.

6) The Path Forward:

• Pre-emptive Testing: Future lies in obtaining genetic profiles before medications are needed, enabling lifelong personalised prescribing.
• Fundamental Shift: Moves healthcare from population-based to individualised, from reactive to proactive, and from trial-and-error to precision medication.
• Genomic Insight: Our genes guide our prescriptions-pharmacogenomics teaches us how to read this biological roadmap.